Aileron Therapeutics, Inc. (ALRN) DCF Valuation

Aileron Therapeutics, Inc. (ALRN) DCF Valuation
  • ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
  • ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
  • ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
  • ✓ No Se Necesita Experiencia; Fáciles De Seguir

Aileron Therapeutics, Inc. (ALRN) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Looking to assess the intrinsic value of Aileron Therapeutics, Inc.? Our (ALRN) DCF Calculator integrates real-world data with extensive customization features, enabling you to refine your forecasts and enhance your investment strategies.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Revenue Growth, % 0 0 0 0 0 0 0 0 0 0
EBITDA -29.8 -20.3 -26.5 -27.5 -15.6 .0 .0 .0 .0 .0
EBITDA, % 100 100 100 100 100 100 100 100 100 100
Depreciation .2 .2 .1 .2 .1 .0 .0 .0 .0 .0
Depreciation, % 100 100 100 100 100 100 100 100 100 100
EBIT -30.0 -20.5 -26.6 -27.6 -15.7 .0 .0 .0 .0 .0
EBIT, % 100 100 100 100 100 100 100 100 100 100
Total Cash 18.3 13.8 45.9 21.2 17.3 .0 .0 .0 .0 .0
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .0 .0 .0 .0 .0
Account Receivables, % 100 100 100 100 100
Inventories .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Inventories, % 100 100 100 100 100 100 100 100 100 100
Accounts Payable 1.5 1.6 1.2 1.7 1.2 .0 .0 .0 .0 .0
Accounts Payable, % 100 100 100 100 100 100 100 100 100 100
Capital Expenditure -.2 .0 -.2 .0 .0 .0 .0 .0 .0 .0
Capital Expenditure, % 100 100 100 100 100 0 0 0 0 0
Tax Rate, % 0 0 0 0 0 0 0 0 0 0
EBITAT -29.4 -21.1 -26.2 -27.3 -15.7 .0 .0 .0 .0 .0
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -27.9 -20.8 -26.6 -26.6 -16.1 -1.2 .0 .0 .0 .0
WACC, % 15.45 15.45 15.45 15.45 15.45 15.45 15.45 15.45 15.45 15.45
PV UFCF
SUM PV UFCF -1.0
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 0
Terminal Value 0
Present Terminal Value 0
Enterprise Value -1
Net Debt -17
Equity Value 16
Diluted Shares Outstanding, MM 5
Equity Value Per Share 3.53

What You Will Get

  • Real ALRN Financial Data: Pre-filled with Aileron Therapeutics' historical and projected data for precise analysis.
  • Fully Editable Template: Modify key inputs like revenue growth, WACC, and EBITDA % with ease.
  • Automatic Calculations: See Aileron Therapeutics' intrinsic value update instantly based on your changes.
  • Professional Valuation Tool: Designed for investors, analysts, and consultants seeking accurate DCF results.
  • User-Friendly Design: Simple structure and clear instructions for all experience levels.

Key Features

  • Comprehensive Financial Data: Obtain precise historical data and forecasts tailored for Aileron Therapeutics, Inc. (ALRN).
  • Adjustable Forecast Parameters: Modify highlighted fields such as discount rates, growth projections, and profit margins.
  • Real-Time Calculations: Automatic recalculations for DCF, Net Present Value (NPV), and cash flow assessments.
  • Interactive Dashboard: User-friendly graphs and summaries for clear visualization of your valuation outcomes.
  • Designed for All Levels: An intuitive layout suitable for investors, financial officers, and consultants alike.

How It Works

  1. Step 1: Download the Excel file.
  2. Step 2: Review pre-entered Aileron Therapeutics data (historical and projected).
  3. Step 3: Adjust key assumptions (yellow cells) based on your analysis.
  4. Step 4: View automatic recalculations for Aileron Therapeutics’ intrinsic value.
  5. Step 5: Use the outputs for investment decisions or reporting.

Why Choose Aileron Therapeutics, Inc. (ALRN) Calculator?

  • Comprehensive Tool: Integrates DCF, WACC, and financial ratio analyses tailored for Aileron Therapeutics.
  • Customizable Inputs: Modify yellow-highlighted cells to explore different financial scenarios for ALRN.
  • Detailed Insights: Automatically computes Aileron’s intrinsic value and Net Present Value.
  • Preloaded Data: Historical and projected data provide accurate foundations for analysis.
  • Professional Quality: Perfect for financial analysts, investors, and consultants focused on biotechnology.

Who Should Use This Product?

  • Investors: Assess Aileron Therapeutics’ valuation before making investment decisions.
  • CFOs and Financial Analysts: Optimize valuation methodologies and evaluate financial forecasts.
  • Startup Founders: Understand the valuation processes of biotech firms like Aileron Therapeutics.
  • Consultants: Provide comprehensive valuation analyses for clients in the healthcare sector.
  • Students and Educators: Utilize current market data to learn and teach valuation strategies.

What the Template Contains

  • Operating and Balance Sheet Data: Pre-filled Aileron Therapeutics historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
  • WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), incorporating parameters such as Beta, risk-free rate, and share price.
  • DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models detailing intrinsic value with comprehensive calculations.
  • Financial Statements: Pre-loaded financial statements (annual and quarterly) to facilitate analysis.
  • Key Ratios: Includes profitability, leverage, and efficiency ratios for Aileron Therapeutics, Inc. (ALRN).
  • Dashboard and Charts: Visual summary of valuation outputs and assumptions to simplify result analysis.

No products were found matching.